Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Lifted by MGO One Seven LLC

MGO One Seven LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 216.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,813 shares of the company's stock after acquiring an additional 33,377 shares during the period. MGO One Seven LLC's holdings in Teva Pharmaceutical Industries were worth $1,076,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares during the period. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $58,243,000. Marshall Wace LLP boosted its holdings in shares of Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after acquiring an additional 2,410,420 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $38,914,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $0.56 during trading hours on Tuesday, hitting $15.58. 14,075,381 shares of the company's stock traded hands, compared to its average volume of 9,953,833. The company's fifty day simple moving average is $15.19 and its two-hundred day simple moving average is $17.55. The company has a market cap of $17.67 billion, a price-to-earnings ratio of -10.74, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on TEVA. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Bank of America cut their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Finally, Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.